GFPC
MYGN icon

Global Financial Private Client’s Myriad Genetics MYGN Stock Holding History

Global Financial Private Client’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3
Closed -$41 – 1689
2024
Q4 		$41 Buy
+3
New +$55 ﹤0.01% 1604

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Global Financial Private Client's MYGN Position: Q1 2025 in Review

Global Financial Private Client sold out of Myriad Genetics (MYGN) in Q1 2025, closing a stake of 3 shares — an estimated $41 sold.

Global Financial Private Client first reported a position in MYGN in Q4 2024 and held it in 1 quarter. The position peaked at $41 in Q4 2024. 228 funds tracked by Wall St. Rank hold MYGN as of Q1 2025.

  • Global Financial Private Client reported no remaining Myriad Genetics position as of Q1 2025 after selling out during the quarter.
  • Global Financial Private Client sold 3 Myriad Genetics shares in Q1 2025, an estimated $41.
  • Global Financial Private Client first reported a position in Myriad Genetics in Q4 2024 and held it in 1 quarter.
  • Global Financial Private Client's Myriad Genetics position peaked at $41 in Q4 2024.
  • 228 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2025.

Based on Global Financial Private Client's 13F filing for Q1 2025, filed 8 Apr 2025.